2 Under-the-Radar Pharma M&A Targets for 2018
A look at why these two biopharma companies could have targets on their backs. Source: BioSpace
A look at why these two biopharma companies could have targets on their backs. Source: BioSpace
The portfolio consists of acute, chronic and oncology products. Source: BioSpace
The company believes the Translarna data is compelling and pointed to the success the drug is having in Europe. Source: BioSpace
Here's a look at the seven best life science companies to work for in 2018. Source: BioSpace
Hyalex Orthopaedics launched in May 2017 as a medical device company that intends to advance new products featuring HYALEX technology, a synthetic polymer that mimics cartilage. Source: BioSpace
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference. Source: BioSpace
Teva has made a target of cutting costs by $3B by the end of 2019. Source: BioSpace
GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay. Source: BioSpace
Dr. Erwin Erfe, head of the PAO Forensic Laboratory, said the 4 children they examined contracted dengue 6 months after receiving the vaccine. Source: BioSpace
Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years. Source: BioSpace